Trending

Advair

Chasing Mylan, Hikma tries again with rejected generic Advair in US

Chasing Mylan, Hikma tries again with rejected generic Advair in US

UK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for

X

Chasing Mylan, Hikma tries again with rejected generic Advair in US

https://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/

Shingrix and Trelegy shield GSK from Advair fallout

Shingrix and Trelegy shield GSK from Advair fallout

GlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs

X

Shingrix and Trelegy shield GSK from Advair fallout

https://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/

Shingles vaccine boosts GSK as generic Advair bites

Shingles vaccine boosts GSK as generic Advair bites

GSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of

X

Shingles vaccine boosts GSK as generic Advair bites

https://pharmaphorum.com/news/shingles-vaccine-boosts-gsk-as-generic-advair-bites/

Advair reprieve gives GSK breathing space

Advair reprieve gives GSK breathing space

GlaxoSmithKline looks set to have another year without US generic competition to its respiratory blockbuster Advair, after the

X

Advair reprieve gives GSK breathing space

https://pharmaphorum.com/news/advair-reprieve-gives-gsk-breathing-space/

GSK’s new pharma chief Miels to join in September

GSK’s new pharma chief Miels to join in September

Luke Miels to start role after GSK and AZ end contract row.

X

GSK’s new pharma chief Miels to join in September

https://pharmaphorum.com/news/gsks-new-pharma-chief-join-september/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com